Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics Inc (NQ: RLAY )

10.94 -0.06 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Relay Therapeutics Inc

< Previous 1 2 3 4 Next >
Relay Therapeutics: Q1 Earnings Insights
 
Via Benzinga
Earnings Outlook For Relay Therapeutics
 
Via Benzinga
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
Evogene employs an artificial intelligence platform for decoding plant phenotypes and microbial genomes. Consider its' research agenda, applications, and at-the-market products. The set-up may present... 
Via Talk Markets
What 11 Analyst Ratings Have To Say About Relay Therapeutics
 
Via Benzinga
Why Relay Therapeutics Stock Is Trading Higher Today
Relay Therapeutics (NASDAQ: RLAY) shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy and announced a $29 price target. Also, the stock is rebounding... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Relay Therapeutics's Return On Capital Employed Overview
 
Via Benzinga
Relay Therapeutics Earnings Preview
 
Via Benzinga
5 Analysts Have This to Say About Relay Therapeutics
Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Relay Therapeutics
Within the last quarter, Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 91 stocks hit new 52-week lows. 
Via Benzinga
4 Analysts Have This to Say About Relay Therapeutics
Within the last quarter, Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
 
Via Benzinga
Why Relay Therapeutics Stock Is Plunging Today
Relay Therapeutics Inc (NASDAQ: RLAY) announced initial clinical data for RLY-2608, an investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα. 
Via Benzinga
Ericsson, Johnson & Johnson, Goldman Sachs And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional... 
Via Benzinga
Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
 
Via Benzinga
Get In Now. 7 Stocks That Are Set to Soar.
While it’s always difficult to determine which stocks to buy might break out imminently, speculators should watch these ideas. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
 
Via Benzinga
Evogene Offers An Excellent Risk/Reward Ratio
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
 
Via Benzinga
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
Relay Therapeutics's Earnings Outlook
Relay Therapeutics (NASDAQ:RLAY) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Relay... 
Via Benzinga
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022
Upgrades 
Via Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
Wells Fargo Slashes Price Target On This Stock By Over 71%, Also Check Out Other Major PT Changes Here
Wells Fargo cut the price target on Cabaletta Bio, Inc. (NASDAQ: CABA) from $14 to $4. Wells Fargo analyst Derek Archila maintained the stock with an Overweight rating. Cabaletta Bio shares gained 0.9%... 
Via Benzinga
Tesla, Meta, NVIDIA And Other Big Losers From Tuesday
U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.